Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Dec 11:2:188.
doi: 10.3389/fonc.2012.00188. eCollection 2012.

Therapy of newly diagnosed follicular lymphoma

Jason R Westin  1 , Sattva S Neelapu
Affiliations

Therapy of newly diagnosed follicular lymphoma

Jason R Westin et al. Front Oncol. .

Abstract

Newly diagnosed follicular lymphoma is relatively common and can be effectively treated with several differing approaches. Although the disease is often considered incurable, it is highly responsive to therapy when indicated. This review discusses the indications for treatment, risk stratification systems, treatment options with supporting clinical trial data, and expected therapeutic outcomes in newly diagnosed follicular lymphoma.

Keywords: B cell; chemotherapy; follicular lymphoma; immunotherapy; lymphoma; newly diagnosed; observation; outcomes.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Follicular lymphoma therapy indications and clinical predictors.
See this image and copyright information in PMC

References

    1. Abramson J. S., Chen W., Juszczynski P., Takahashi H., Neuberg D., Kutok J. L., et al. (2009). The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas. Br. J. Haematol. 144 358–366 - PMC - PubMed
    1. Advani R., Forero-Torres A., Furman R. R., Rosenblatt J. D., Younes A., Shankles B., et al. (2006). SGN-40 (anti-huCD40 mAb) monotherapy induces durable objective responses in patients with relapsed aggressive non-Hodgkin’s lymphoma: evidence of antitumor activity from a phase I study. Blood 108 abstr. 695
    1. Advani R. H., Buggy J. J., Sharman J. P., Smith S. M., Boyd T. E., Grant B., et al. (2012). Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol. 10.1200/jco.2012.42.7906 [Epub ahead of print]. - DOI - PMC - PubMed
    1. Al-Tourah A. J., Gill K. K., Chhanabhai M., Hoskins P. J., Klasa R. J., Savage K. J., et al. (2008). Population-based analysis of incidence and outcome of transformed non-Hodgkin’s lymphoma. J. Clin. Oncol. 26 5165–5169 - PubMed
    1. Ardeshna K., Smith P., Qian W., Warden J., Stevens L., Pocock C., et al. (2010). An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis. Blood 116 abstr. 6

LinkOut - more resources